Tritonix.ai

News / Taiwan / cnyes

Mabtech (4726) Reports 131% Surge in August Revenue

Health Technology · Biotechnology · cnyes · 2026-09-08

4726

Mabtech announced its August 2026 revenue reached NT$106 million, marking a 131.44% year-over-year increase and a 23.14% monthly growth.

What Happened

Revenue Performance: Mabtech (4726) reported a strong revenue figure of NT$106 million for August 2026. This represents a significant year-over-year growth of 131.44% and a monthly increase of 23.14%.

Cumulative Results: For the first eight months of 2026, the company's cumulative revenue reached NT$592 million. This reflects a solid year-to-date growth rate of 36.96% compared to the same period last year.

Market Context: The stock price closed at NT$23.9, with a slight decline of 0.42% over the past five trading days. This performance is relatively in line with the broader biotechnology index, which fell by 0.91% during the same period.

Institutional Activity: Institutional investors have shown a cautious stance, with a net sell-off of 153 shares by foreign investors over the last five days. Domestic institutional investors, including investment trusts and proprietary traders, have remained inactive in the stock.

Read original

More in Health Technology

Genovate August Revenue Surges 50% as Hormone Plant Clears Japanese Regulatory Hurdle

Health Technology · economic_daily · 2026-09-08

Genovate's August revenue grew 50% year-over-year, bolstered by strong sales in oncology and women's health, alongside a key regulatory approval from Japan's PMDA.

4114

Analysts Lower 2026 EPS Forecast for Bora Pharmaceuticals to NT$17.43

Health Technology · cnyes · 2026-09-08

Following a recent FactSet survey, analysts have adjusted their 2026 EPS forecast for Bora Pharmaceuticals downward to NT$17.43, with a target price of NT$505.

6472

Novartis Shares Slide 10% Following Third Clinical Trial Failure in Seven Days

Health Technology · cnbc · 2026-09-08

Novartis stock dropped sharply after the company reported that its del-desiran treatment for a muscle-wasting condition failed to meet late-stage study goals.

NVS, EWL

Latest in Taiwan

CHPT August Profit Surges 95%; ShunSin Revenue Hits Record High

Electronic Technology · economic_daily · 2026-09-08

CHPT reports a 95% year-over-year profit jump for August, while ShunSin-KY posts record monthly revenue as both companies ramp up investments in AI and advanced packaging.

Wistron GDR Priced at 5.5% Discount; Shares Slide

Electronic Technology · economic_daily · 2026-09-08

Wistron has finalized the pricing for its Global Depositary Receipt offering at a 5.5% discount, leading to a 5.33% drop in share price as investors react.

3231

Shin Kong Synthetic Fibers Enters Drone Market to Capture Low-Altitude Economy

Process Industries · cnyes · 2026-09-08

Shin Kong Synthetic Fibers (1409-TW) has partnered with Aero-Tech and JEDSY to form a joint venture, marking its strategic entry into drone materials and systems.

1409

Chien Fu Enterprise's 8-Month Revenue Surpasses Full-Year 2025 Total

Electronic Technology · cnyes · 2026-09-08

Chien Fu Enterprise (8383-TW) reported that its cumulative revenue through August has already exceeded its total 2025 annual revenue, driven by strong semiconductor demand.

6829, 8383